dhr

#股票财报季
#DHR

企业判断： 丹纳赫已经出现具有现实依据的经营复苏，生物工艺订单与自由现金流改善尤其值得肯定。但本季度报告收入受到收购并表支持，净利润受到一次性税务收益支持，尚不足以证明企业已经全面恢复高速增长。

投资判断： 当前估值已反映持续复苏及并购协同预期。现有证据不足以认定丹纳赫明显低估，后续投资价值取决于核心收入增长能否加速，以及收购资本能否创造足够的长期现金回报。

DHR’s recovery is finally getting clearer $DHR 🧪

Danaher opened 2026 with $6.0B in revenue, $2.06 in adjusted EPS, and $1.1B in free cash flow, which tells institutions the quality of earnings is still holding up. The real signal is the guidance bump and Biotechnology’s 7.0% core growth, while Diagnostics remains the drag; this is shaping up like a slow, selective rebound rather than a broad snapback.

Money tends to rotate toward the cleanest growth first, and biotech is clearly carrying the load while the other segments heal. If that strength spreads and the Masimo deal adds another layer of upside, the tape could keep attracting patient capital even without a loud market reaction.

Not financial advice. Manage your risk and protect your capital.

#DHR #Earnings #Stocks #Investing #Biotech

✦